Status:
RECRUITING
MAX - SHOCK Clinical Trial
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Conditions:
Cardioversion
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Can Electrical Cardioversion (ECV) for AF be improved. It is the preferred method to restore sinus rhythm in patients with AF in whom a rhythm-control strategy is pursued. Hypothesis: ECV success ra...
Detailed Description
Published estimates of ECV success using modern biphasic defibrillators vary considerably but most are limited by small sample sizes. Our pre-intervention ECV success rate of 91.8% was stable over \>2...
Eligibility Criteria
Inclusion
- Patients age \> 18 years.
- Persistent atrial fibrillation.
- Scheduled for elective cardioversion at UOHI
- Patient is within the circle of care of UOHI Electrophysiology staff
Exclusion
- Known left-atrial appendage thrombus.
- Contraindication to appropriate anticoagulation.
- Patient is included in another randomized clinical trial.
- Patient does not meet all of the above listed inclusion criteria.
Key Trial Info
Start Date :
March 31 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
379 Patients enrolled
Trial Details
Trial ID
NCT06556667
Start Date
March 31 2025
End Date
September 1 2027
Last Update
August 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7